GlassScriptPhysician profile
Angelique Mole
NPI 1659877264
$1,586.79
in general payments reported to CMS, 2019-2025
20 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.99 · 2020: $17.51 · 2021: $232 · 2022: $159 · 2023: $261 · 2024: $509 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $283.56 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $263.63 | 2021-2025 | Farxiga, Airsupra |
| Viiv Healthcare Company | $147.75 | 2023-2025 | Dovato, Cabenuva |
| Merck Sharp & Dohme LLC | $132.81 | 2024-2025 | Pifeltro, Delstrigo |
| Lilly USA, LLC | $113.03 | 2022-2024 | Mounjaro, Jardiance |
| Abbvie INC. | $112.39 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.14 | 2021-2025 | |
| Exact Sciences Corporation | $82.49 | 2023-2025 | Cologuard Collection Kit |
| Theratechnologies INC. | $56.24 | 2023-2025 | Trogarzo, Egrifta |
| Pfizer INC. | $56.21 | 2021-2024 | |
| Glaxosmithkline, LLC. | $55.02 | 2022-2023 | Shingrix, Pediarix, Bexsero |
| Novartis Pharmaceuticals Corporation | $38.84 | 2021-2022 | |
| Kyowa Kirin, INC. | $22.73 | 2024 | Crysvita |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.02 | 2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $19.90 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $17.51 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.22 | 2024 | Voquezna |
| Corcept Therapeutics | $14.51 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $14.25 | 2024 | Rexulti |
| Gilead Sciences, INC. | $13.54 | 2023 | Epclusa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelique Mole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.